SCHEMBL13310280

SCHEMBL13310280

O=C(O)c1ccccc1Nc1nc2nonc2nc1Nc1ccccc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MYC P01106 1/20 0.50
AURKA O14965 6/20 0.48
MAPK8 P45983 4/20 0.48
CDC7 O00311 1/20 0.48
ALK Q9UM73 1/20 0.48
FABP3 P05413 2/20 0.47
FABP5 Q01469 2/20 0.47
TAS2R14 Q9NYV8 2/20 0.47
AKR1B10 O60218 1/20 0.45
TRPA1 O75762 1/20 0.45
ABCB11 O95342 1/20 0.45
DHFR P00374 1/20 0.45
LMNA P02545 1/20 0.45
MPO P05164 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CHRM1 P11229 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20571058 0.84 MAPT (0.55) MEN1KMT2AAURKAPTGS2KDM4E
SCHEMBL355549 0.75 FABP4 (0.80) FABP4MEN1KMT2AFABP3FABP5
SCHEMBL30320327 0.75 FABP4 (0.80) FABP4MEN1KMT2AFABP3FABP5
SCHEMBL20570269 0.75 TP53 (0.67) MEN1KMT2ALMNACYP1A2CYP2C9
SCHEMBL29603638 0.74 AURKA (0.66) FABP4MEN1KMT2AAURKAMAPK8
SCHEMBL5686015 0.74 AURKA (0.66) FABP4MEN1KMT2AAURKAMAPK8
SCHEMBL6142375 0.73 FABP4 (0.84) FABP4MEN1KMT2AFABP3FABP5
SCHEMBL9691899 0.73 FABP4 (0.77) FABP4MEN1KMT2AFABP3FABP5
SCHEMBL3051333 0.72 MAPT (0.54) MEN1KMT2ALMNAPTGS1PTGS2
SCHEMBL20569985 0.71 SMN1; SMN2 (0.51) MEN1KMT2AMYCAURKALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445677-B2 Substituted pyrimidyl guanidine derivatives having anticancer activity UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2013-05-21 US disclosed
US-8445677-B2 Substituted pyrimidyl guanidine derivatives having anticancer activity UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2013-05-21 US disclosed
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2010-06-24 US disclosed
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE ABCG2, NQO2, TOP1 FABP4 4834/4885MEN1 1470/4885KMT2A 1733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.